<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404805</url>
  </required_header>
  <id_info>
    <org_study_id>15-0106</org_study_id>
    <secondary_id>152252</secondary_id>
    <nct_id>NCT02404805</nct_id>
  </id_info>
  <brief_title>Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers</brief_title>
  <official_title>Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator believes simeprevir concentrations are unchanged when administered in
      combination with dolutegravir relative to administration alone. The investigator believes
      dolutegravir concentrations are unchanged when administered in combination with simeprevir.
      Additionally, the investigator believes simeprevir and dolutegravir are safe when
      administered alone and in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the potential for drug interactions between simeprevir and dolutegravir,
      participants will receive each drug alone and the drugs in combination for 7 days. The
      pharmacokinetics of simepervir and dolutegravir when given in combination vs. alone will be
      compared.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Simeprevir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine simeprevir area-under-the concentration time curve (AUC) when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dolutegravir AUC Pharmacokinetics</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine dolutegravir area-under-the concentration time curve (AUC) when administered alone.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simeprevir AUC Pharmacokinetics Coadministered With Dolutegravir</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine simeprevir AUC when coadministered with dolutegravir. [Ratio = simeprevir administered with dolutegravir/simeprevir alone]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dolutegravir AUC Pharmacokinetics Coadministered With Simeprevir</measure>
    <time_frame>Pre-dose and, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours post-dose on day 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Determine dolutegravir AUC when coadministered with simeprevir. [Ratio = dolutegravir administered with simeprevir/dolutegravir alone]</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>HIV</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,2,3: simeprevir only, then dolutegravir only, then both simeprevir and dolutegravir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 1,3,2: simeprevir only, then both simeprevir and dolutegravir, then dolutegravir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,1,3: dolutegravir only, then simeprevir only, then both simeprevir and dolutegravir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 2,3,1: dolutegravir only, then both simeprevir and dolutegravir, then simeprevir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,1,2: both simeprevir and dolutegravir, then simeprevir only, then dolutegravir only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence 3,2,1: Both simeprevir and dolutegravir, then dolutegravir only, then simeprevir only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir</intervention_name>
    <description>dolutegravir tablets 50mg, once daily x 7 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simeprevir</intervention_name>
    <description>simeprevir tablets 150mg, once daily x 7 days.</description>
    <arm_group_label>Sequence 1a</arm_group_label>
    <arm_group_label>Sequence 1b</arm_group_label>
    <arm_group_label>Sequence 2a</arm_group_label>
    <arm_group_label>Sequence 2b</arm_group_label>
    <arm_group_label>Sequence 3a</arm_group_label>
    <arm_group_label>Sequence 3b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ages 18-60 years

          -  Absence of HIV-1 and HCV antibodies at screening,

          -  Ability and willingness to give written informed consent before the first
             trial-related activity.

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Active alcohol or drug abuse that, in the opinion of the investigators, would
             interfere with adherence to study requirements

          -  Participation in any investigational drug study within 30 days prior to study entry

          -  Currently active or chronic gastrointestinal, cardiovascular, neurologic,
             psychiatric, metabolic, renal, hepatic, respiratory, inflammatory, or infectious
             disease or malignancy requiring pharmacologic treatment, and/or if in the opinion of
             the investigator, would affect study participation, safety, or integrity of results

          -  Use of concomitant medication, including investigational, prescription, and
             over-the-counter products and dietary supplements with the following exceptions:
             aspirin, acetaminophen, ibuprofen, hormonal oral contraceptives

          -  Concomitant medications other than those listed above must have been discontinued at
             least 14 days before study entry

          -  Currently active dermatitis or urticaria or diagnosis of eczema or psoriasis,

          -  History of significant drug allergy (i.e., anaphylaxis and/or angioedema)

          -  Subjects with the following laboratory abnormalities at screening as defined by the
             2004 Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse
             Events (&quot;DAIDS grading table&quot;) and in accordance with the normal ranges of the trial
             clinical laboratory: serum creatinine grade 1 or greater (≥ 1.1 x upper limit of
             laboratory normal range (ULN)); hemoglobin grade 1 or greater (≤ 10.9 g/dL); platelet
             count grade 1 or greater (≤ 124.999 x 109/L); absolute neutrophil count grade 1 or
             greater (≤ 1.3 x 109/L); aspartate aminotransferase (AST) or alanine aminotransferase
             (ALT) grade 1 or greater (≥ 1.25 x ULN); total bilirubin grade 1 or greater (≥ 1.1 x
             ULN), any other laboratory abnormality of grade 2 or above.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer J Kiser, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan T Huntley, B.S.</last_name>
    <phone>303-724-5564</phone>
    <email>ryan.huntley@ucdenver.edu</email>
  </overall_contact>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>September 11, 2015</lastchanged_date>
  <firstreceived_date>March 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dolutegravir</keyword>
  <keyword>simeprevir</keyword>
  <keyword>HIV</keyword>
  <keyword>HCV</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
